Align Technology's (ALGN) stock plummeted 6.35% in the 24 hours leading up to the post-market session on Wednesday. The medical device company, known for its Invisalign clear aligners, reported mixed fourth-quarter 2024 results and issued a disappointing revenue guidance for the first quarter of 2025.
For Q4 2024, Align Technology's revenue grew 4% year-over-year to $995.2 million, slightly beating analysts' estimates. However, the company's adjusted earnings per share (EPS) of $2.44 missed expectations, coming in at $1.39. The miss was primarily attributed to unfavorable foreign exchange rates and restructuring charges related to post-employment benefits.
More concerning for investors was Align Technology's revenue guidance for Q1 2025. The company expects revenue between $965 million and $985 million, falling short of analysts' consensus estimate of $1.03 billion. This guidance suggests softer demand for Align's clear aligners, particularly among teenage and younger patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.